+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Helicobacter Pylori Non-invasive Testing Market by Test Type, End User, Technology, Distribution Channel - Global Forecast to 2030- Product Image
Helicobacter Pylori Non-invasive Testing Market by Test Type, End User, Technology, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Helicobacter Pylori Non-invasive Testing Market by Test Type, End User, Technology, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904519
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Helicobacter Pylori Non-invasive Testing Market grew from USD 1.12 billion in 2024 to USD 1.19 billion in 2025. It is expected to continue growing at a CAGR of 5.73%, reaching USD 1.57 billion by 2030.

Unveiling the Pervasive Challenge of Helicobacter Pylori

Helicobacter Pylori infection remains a pervasive global health challenge, affecting billions and contributing to gastritis, peptic ulcers, and even gastric malignancies. As awareness of its clinical significance grows, non-invasive testing methods have emerged as critical tools for early detection and management. These approaches offer an attractive blend of patient comfort, diagnostic accuracy, and operational efficiency compared to traditional endoscopic biopsies.

Recent shifts in healthcare delivery, including the rise of outpatient care and telemedicine, have underscored the need for reliable, easy-to-administer tests that minimize patient burden and resource utilization. Clinicians and laboratories are increasingly prioritizing tests that deliver rapid results with high sensitivity and specificity, facilitating timely treatment decisions and reducing the risk of complications.

This executive summary distills the latest developments in Helicobacter Pylori non-invasive diagnostics. By examining market drivers, regulatory catalysts, tariff impacts, segment-specific insights, regional nuances, and competitive dynamics, we provide a structured overview for decision-makers aiming to navigate this dynamic landscape and capitalize on emerging opportunities.

Catalysts Driving Evolution in Non-invasive Diagnostics

The diagnostic landscape for Helicobacter Pylori has been reshaped by technological breakthroughs, pushing the boundaries of accuracy and accessibility. Innovations in assay chemistry, such as enhanced monoclonal antibody reagents for stool antigen tests, have driven sensitivity rates to new heights, while rapid immunoassays deliver actionable results within minutes, improving clinical workflow efficiency.

Regulatory bodies in key markets are adapting guidelines to encourage non-invasive methods. Streamlined approvals for urea breath tests, particularly those leveraging 13C isotopes, have reduced barriers to adoption, while evolving reimbursement policies are incentivizing providers to integrate serology and stool antigen testing into routine gastric health screenings.

Simultaneously, patient-centric care models are gaining traction. Home-based sampling kits for stool antigen tests and point-of-care breath testing devices are empowering patients to participate actively in their diagnostic journey. These shifts are fostering a more proactive approach to Helicobacter Pylori management, with early detection and monitoring strategies becoming integral to chronic disease prevention.

Navigating the Implications of Tariff Revisions on Market Dynamics

The United States’ tariff revisions scheduled for 2025 are poised to influence the cost structure of diagnostic kits and consumables. Increased duties on imported reagent kits and analytical instruments could elevate manufacturing expenses, particularly for manufacturers reliant on overseas suppliers of specialized antibodies and isotopic substrates.

These changes may cascade through the supply chain, prompting distributors and end users to reassess pricing strategies. While larger diagnostic laboratories may absorb portions of the cost increase, smaller clinics and point-of-care settings could face margin pressures, potentially limiting access in rural or underserved regions.

To mitigate these effects, stakeholders are exploring local sourcing partnerships, regional manufacturing alliances, and strategic inventory management. By diversifying supply chains and renegotiating supplier contracts, industry players can safeguard test affordability and ensure steady product availability despite tariff-induced cost fluctuations.

Decoding Market Segments Through Test Types, End Users, Technologies, and Channels

An in-depth examination by test type reveals a nuanced distribution of market share and growth potential. Serology tests, which encompass IGa, IGg, and IGm assays, continue to serve as cost-effective screening tools, while stool antigen tests-driven by monoclonal and polyclonal antibody formats-offer superior sensitivity in detecting active infections. Urea breath tests, available in both 13C and 14C isotopic variants, remain the diagnostic gold standard in many regions due to their non-invasive nature and high specificity.

From an end user perspective, clinics-particularly those specializing in gastroenterology and primary care-have emerged as pivotal access points for initial testing, leveraging streamlined workflows and patient relationships. Secondary care and tertiary hospitals maintain a critical role for confirmatory testing and complex case management, while diagnostic laboratories and point-of-care settings provide high-throughput and rapid result delivery, respectively.

Technological segmentation highlights immunoassays, including ELISA and rapid formats, as the mainstay for serology and stool antigen detection. Infrared spectrometry offers innovative avenues for microbial metabolite analysis, whereas mass spectrometry techniques-spanning GC-MS and LC-MS-enable unparalleled analytical precision for isotopic breath testing.

Distribution channels exhibit diverse reach: direct-to-customer models facilitate hospital and laboratory procurement, online sales platforms expand market access for home testing kits, and wholesale distributors-both national and regional-ensure consistent supply across geographies. This multi-layered segmentation framework informs targeted strategies for product development, marketing, and channel optimization.

Regional Variations Shaping the Global Testing Landscape

In the Americas, a robust healthcare infrastructure and proactive screening guidelines have driven early adoption of urea breath tests and advanced immunoassay kits. Market growth is further supported by widespread insurance coverage and national initiatives aimed at reducing gastric cancer incidence. This region’s dynamic private-public partnerships have accelerated product approvals and distribution networks.

Europe, Middle East & Africa present a heterogeneous landscape. Western European nations exhibit mature diagnostic ecosystems with high demand for precision breath testing, while emerging markets in the Middle East and Africa are witnessing rapid uptake of cost-effective stool antigen and serology assays. Economic disparities and healthcare access variability underscore the need for adaptable pricing and distribution approaches.

Asia-Pacific stands out for its large patient populations and increasing healthcare expenditure. Countries such as Japan and South Korea lead in adopting 13C urea breath tests, supported by strong reimbursement frameworks. In contrast, Southeast Asian and South Asian markets rely heavily on rapid immunoassays and stool antigen tests due to favorable cost structures and expanding primary care networks.

These regional nuances reveal opportunities for tailored market entry strategies, indicating where investments in education, distribution infrastructure, and localized manufacturing can yield the greatest impact.

Competitive Dynamics Among Leading Test Providers

Leading diagnostics firms are intensifying efforts to differentiate through proprietary assay platforms and strategic alliances. Some companies are channeling R&D investments into next-generation immunoassays that reduce cross-reactivity and improve throughput, while others are forging partnerships with academic institutions to accelerate biomarker discovery and validation.

Competition is also playing out through geographic expansion and localized production facilities. By establishing regional manufacturing hubs, key players are not only mitigating tariff exposure but also shortening delivery times and customizing product portfolios to meet local regulatory requirements.

Moreover, mergers and acquisitions are reshaping the competitive field. Consolidation among reagent suppliers and instrumentation providers is creating end-to-end solution offerings, enabling certain companies to capture greater value across the diagnostic workflow. This trend underscores the importance of integrated service models that combine testing kits, analytical equipment, and data management software.

Strategic Imperatives for Enhancing Market Position

Industry leaders should prioritize investment in advanced assay development, leveraging cutting-edge immunochemistry and isotopic analysis to stay ahead of emerging pathogens and evolving clinical needs. Collaborative ventures with technology innovators can accelerate time to market and foster sustained innovation.

Expanding distribution networks through direct partnerships with university hospitals, primary care chains, and specialized clinics will enhance market penetration. Tailored educational programs for clinicians and laboratory technicians can further drive test adoption and ensure proper application protocols.

Adaptive pricing models, such as volume-based discounts and subscription services for continuous reagent supplies, will help maintain affordability across diverse end users. Differentiation through value-added services, including digital result integration and teleconsultation support, can strengthen customer loyalty.

A nuanced regional strategy is essential: in mature markets, emphasize premium breath testing products, whereas in cost-sensitive regions, focus on scalable immunoassay and stool antigen solutions. Robust supply chain planning, underpinned by dual sourcing and buffer inventories, will mitigate potential disruptions from tariff changes and logistical challenges.

Rigorous Framework Underpinning Our Analysis

This analysis is founded on a rigorous, multi-tiered research framework designed to ensure accuracy and relevance. Primary research included in-depth interviews with leading gastroenterologists, laboratory directors, and procurement specialists, providing firsthand insights into diagnostic preferences and decision drivers.

Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings, company annual reports, and proprietary industry databases. This literature formed the basis for mapping technological advancements and competitive landscapes.

Quantitative data was cross-validated through triangulation methods, comparing findings from disparate sources to identify and resolve inconsistencies. Statistical analyses and trend extrapolations were conducted to elucidate market dynamics without undertaking explicit forecasting.

To maintain methodological integrity, all data points were subjected to quality checks, with outliers and anomalies investigated through follow-up consultations. This structured approach ensures that the insights presented are both robust and actionable, reflecting the latest developments in non-invasive Helicobacter Pylori diagnostics.

Synthesis of Findings and Strategic Outlook

The landscape of Helicobacter Pylori non-invasive testing is characterized by rapid technological innovation, shifting regulatory incentives, and evolving market forces. Key drivers include the pursuit of patient-friendly diagnostics, the imperative for cost containment, and the strategic mobilization of distribution channels.

Tariff adjustments in the United States underscore the importance of supply chain resilience and proactive cost management. Meanwhile, segmentation insights highlight the need for differentiated product portfolios tailored to the unique requirements of end users, technologies, and distribution pathways.

Regional contrasts further demonstrate that no single strategy will suffice; instead, agile market approaches that address local healthcare priorities and economic constraints are essential. As leading companies vie for share through innovation and strategic alliances, the competitive intensity will continue to escalate.

In summary, stakeholders equipped with a deep understanding of these multifaceted trends and armed with targeted recommendations will be best positioned to capitalize on the expanding opportunities within the non-invasive Helicobacter Pylori testing arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Serology Test
      • IGa Test
      • IGg Test
      • IGm Test
    • Stool Antigen Test
      • Monoclonal Antibody Test
      • Polyclonal Antibody Test
    • Urea Breath Test
      • 13C Urea Breath Test
      • 14C Urea Breath Test
  • End User
    • Clinics
      • Gastroenterology Clinic
      • Primary Care Clinic
    • Diagnostic Laboratories
    • Hospitals
      • Secondary Care Hospital
      • Tertiary Care Hospital
    • Point Of Care
  • Technology
    • Immunoassay
      • Elisa
      • Rapid Immunoassay
    • Infrared Spectrometry
    • Mass Spectrometry
      • Gc Ms
      • Lc Ms
  • Distribution Channel
    • Direct To Customer
      • Hospital Direct
      • Laboratory Direct
    • Hospital Procurement
    • Online Sales
    • Wholesale Distributors
      • National Distributors
      • Regional Distributors
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • bioMérieux SA
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • QIAGEN N.V.
  • DiaSorin S.p.A.
  • Meridian Bioscience, Inc.
  • SD BIOSENSOR Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Helicobacter Pylori Non-invasive Testing Market, by Test Type
8.1. Introduction
8.2. Serology Test
8.2.1. IGa Test
8.2.2. IGg Test
8.2.3. IGm Test
8.3. Stool Antigen Test
8.3.1. Monoclonal Antibody Test
8.3.2. Polyclonal Antibody Test
8.4. Urea Breath Test
8.4.1. 13C Urea Breath Test
8.4.2. 14C Urea Breath Test
9. Helicobacter Pylori Non-invasive Testing Market, by End User
9.1. Introduction
9.2. Clinics
9.2.1. Gastroenterology Clinic
9.2.2. Primary Care Clinic
9.3. Diagnostic Laboratories
9.4. Hospitals
9.4.1. Secondary Care Hospital
9.4.2. Tertiary Care Hospital
9.5. Point of Care
10. Helicobacter Pylori Non-invasive Testing Market, by Technology
10.1. Introduction
10.2. Immunoassay
10.2.1. Elisa
10.2.2. Rapid Immunoassay
10.3. Infrared Spectrometry
10.4. Mass Spectrometry
10.4.1. Gc Ms
10.4.2. Lc Ms
11. Helicobacter Pylori Non-invasive Testing Market, by Distribution Channel
11.1. Introduction
11.2. Direct to Customer
11.2.1. Hospital Direct
11.2.2. Laboratory Direct
11.3. Hospital Procurement
11.4. Online Sales
11.5. Wholesale Distributors
11.5.1. National Distributors
11.5.2. Regional Distributors
12. Americas Helicobacter Pylori Non-invasive Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Helicobacter Pylori Non-invasive Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Helicobacter Pylori Non-invasive Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. F. Hoffmann-La Roche AG
15.3.2. Abbott Laboratories
15.3.3. bioMérieux SA
15.3.4. Danaher Corporation
15.3.5. Thermo Fisher Scientific Inc.
15.3.6. Siemens Healthineers AG
15.3.7. QIAGEN N.V.
15.3.8. DiaSorin S.p.A.
15.3.9. Meridian Bioscience, Inc.
15.3.10. SD BIOSENSOR Co., Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET MULTI-CURRENCY
FIGURE 2. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET MULTI-LANGUAGE
FIGURE 3. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGA TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGG TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IGM TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY 13C UREA BREATH TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY 14C UREA BREATH TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GASTROENTEROLOGY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY PRIMARY CARE CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SECONDARY CARE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TERTIARY CARE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY INFRARED SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY GC MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LC MS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITAL DIRECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY LABORATORY DIRECT, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITAL PROCUREMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 82. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 83. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 84. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 86. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 89. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 90. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 92. CANADA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 95. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 96. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 97. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 103. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 161. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 162. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 163. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 165. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 168. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 169. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 171. GERMANY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 173. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 174. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 175. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 176. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 181. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 182. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 184. FRANCE HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 198. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 199. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 200. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 201. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 202. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 204. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 205. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 207. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 208. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 210. ITALY HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 211. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 213. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 214. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 215. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 217. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 220. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 221. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 223. SPAIN HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 263. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 264. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
TABLE 265. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY STOOL ANTIGEN TEST, 2018-2030 (USD MILLION)
TABLE 266. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY UREA BREATH TEST, 2018-2030 (USD MILLION)
TABLE 267. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 269. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 272. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 273. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 274. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY DIRECT TO CUSTOMER, 2018-2030 (USD MILLION)
TABLE 275. DENMARK HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY WHOLESALE DISTRIBUTORS, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS HELICOBACTER PYLORI NON-INVASIVE TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 277.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Helicobacter Pylori Non-invasive Testing market report include:
  • F. Hoffmann-La Roche AG
  • Abbott Laboratories
  • bioMérieux SA
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • QIAGEN N.V.
  • DiaSorin S.p.A.
  • Meridian Bioscience, Inc.
  • SD BIOSENSOR Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.57 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Helicobacter Pylori Diagnostics Market by Test Type, Product Type, End User, Technology - Global Forecast to 2030 - Product Image

Helicobacter Pylori Diagnostics Market by Test Type, Product Type, End User, Technology - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Non-invasive Helicobacter Pylori Testing - Global Strategic Business Report - Product Image

Non-invasive Helicobacter Pylori Testing - Global Strategic Business Report

  • Report
  • 176 Pages
  • Global
From
Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Helicobacter Pylori Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Helicobacter Pylori Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Helicobacter Pylori Diagnostic Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Helicobacter Pylori Diagnostics - Global Strategic Business Report - Product Image

Helicobacter Pylori Diagnostics - Global Strategic Business Report

  • Report
  • 158 Pages
  • Global
From

About the Helicobacter Pylori Non Invasive Testing Market

Within the realm of infectious disease testing, Helicobacter pylori (H. pylori) non-invasive testing plays a crucial role in the detection of the bacterium H. pylori, which is known to cause various gastrointestinal conditions, including gastritis, ulcers, and certain types of stomach cancer. Non-invasive testing methods are particularly advantageous as they can be administered without the need for endoscopic procedures. These tests include urea breath tests, stool antigen tests, and serological tests that detect antibodies against H. pylori in the blood. The market for H. pylori non-invasive testing is comprised of various test products that cater to the needs of different healthcare settings, from hospitals to clinics and even home testing environments. The development of accurate and user-friendly test kits allows for timely diagnosis and treatment, which is crucial in managing H. pylori-related infections. Moreover, advancements in testing technology have led to the improvement of test sensitivity and specificity, making non-invasive tests a reliable alternative to invasive diagnostic methods. Some companies operating within the H. pylori non-invasive testing market include DiaSorin, Thermo Fisher Scientific, Meridian Bioscience, Bio-Rad Laboratories, and Abbott Laboratories. These companies offer a range of products designed to detect H. pylori infection with varying methods of analysis, contributing to advances in non-invasive diagnostics and expanding the options available for healthcare providers and their patients. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.